Wegovy (semaglutide) tablets 25 mg In addition to diet and exercise to reduce the risk of MACE (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight, and for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity

ibuprofen absorption timing is unpredictable Preferred OTC alternative / acetaminophen 325-650 mg per dose, max 3 to 000 mg/day for most adults Alcohol safety / moderate intake is not prohibited but worsens GI side effects and blood sugar variability Birth control risk window / first 4-8 weeks of semaglutide, vomiting can impair oral contraceptive absorption Pregnancy / semaglutide must be stopped at least 2 months before a planned conception attempt Time to meaningful weight loss / most patients see 5% body-weight reduction by weeks 12-16 at maintenance dose SELECT trial finding / semaglutide 2.4 mg cut major adverse cardiovascular events by 20% in non-diabetic adults with obesity STEP-1 weight loss / 14.9% mean body weight reduction at 68 weeks vs
Physical activity recommendations Exercise makes semaglutide work better and improves your overall health
This is the same recommendation the American Heart Association makes for cardiovascular health, but it has direct benefits for gut motility too
The expression of TNF-, IL-6, IL-1, NF-B, CYP17A1, and StAR in the ovary was significantly downregulated, whereas CYP19A1 expression was upregulated after the intervention